Alzamend Neuro Q2 2025 Earnings Report $1.19 +0.03 (+2.59%) As of 04:00 PM Eastern Earnings HistoryForecast Alzamend Neuro EPS ResultsActual EPS-$0.40Consensus EPS -$2.38Beat/MissBeat by +$1.98One Year Ago EPSN/AAlzamend Neuro Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AAlzamend Neuro Announcement DetailsQuarterQ2 2025Date12/11/2024TimeAfter Market ClosesConference Call ResourcesALZN Earnings History Alzamend Neuro Earnings HeadlinesAlzamend Neuro to Present at the Sequire Investor SummitJanuary 15, 2025 | stockhouse.comAlzamend Neuro to Present Non-Clinical Data Update at the Society of Toxicology 2025 Annual Meeting and ToxExpoDecember 19, 2024 | finance.yahoo.comTesla Shares Soar After Trump Win (Act Now)Are you ready to see why Tesla might be the biggest opportunity on the market today? Right now, Tesla stock is at a critical juncture, and Lance believes it’s primed for explosive growth. That’s why he’s giving away his eBook, The Bullish Case for Tesla, for FREE—but only for a limited time.January 21, 2025 | WealthPress (Ad)Alzamend Neuro says net cash gained by financing activity $8.3MDecember 12, 2024 | markets.businessinsider.comEXCLUSIVE: Alzamend Neuro Reveals Full Data From Nonclinical Study Of Its Lead Alzheimer's Drug PotentialNovember 19, 2024 | finance.yahoo.comAlzamend Neuro regains Nasdaq compliance with equity ruleOctober 17, 2024 | uk.investing.comSee More Alzamend Neuro Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Alzamend Neuro? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Alzamend Neuro and other key companies, straight to your email. Email Address About Alzamend NeuroAlzamend Neuro (NASDAQ:ALZN), an early clinical-stage biopharmaceutical company, focuses on developing various products for the treatment of neurodegenerative and psychiatric disorders. The company's pipeline includes AL001, which delivers a therapeutic combination of lithium, proline, and salicylate for the treatment of Alzheimer's, bi-polar disorder, post-traumatic stress disorder, major depressive disorder, other neurodegenerative diseases, and psychiatric disorders; and ALZN002 stage, which uses a method using a mutant-peptide sensitized cell as a cell-based therapeutic vaccine to restore the ability of a patient's immunological system to combat Alzheimer's disease. Alzamend Neuro, Inc. was incorporated in 2016 and is headquartered in Atlanta, Georgia.View Alzamend Neuro ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles Why Amazon’s Next Earnings Could Trigger a Stock BreakoutS&P 500 Earnings Set to Shine: January's Critical Market TestCiena Rebounds: AI and Strong Guidance Drive Post-Earnings SurgeHistory Hints at a Rebound for Toll Brothers After EarningsAlibaba Stock: Why Earnings Make It a Buy Despite the Recent DipMercadoLibre Down 23% After Missed Earnings: Time to Buy the Dip?Roblox Stock Soars 22% After Q3 Earnings – A Turning Point Ahead? Upcoming Earnings Abbott Laboratories (1/22/2025)Amphenol (1/22/2025)GE Vernova (1/22/2025)ICICI Bank (1/22/2025)Johnson & Johnson (1/22/2025)Kinder Morgan (1/22/2025)Procter & Gamble (1/22/2025)Progressive (1/22/2025)Travelers Companies (1/22/2025)CSX (1/23/2025) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
